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1. Introduction
At the advent of research into natural products, organic
chemistry was a crucial tool to establish the chemical
structure of compounds. As a result, high-yielding, versatile,
and specific synthetic methods were developed, which led,
with the help of innovative strategies, to the production of
natural products in quantities that otherwise would be
inaccessible from natural sources and finally enabled more-
thorough biological evaluation. Once organic chemists could
harness the power of synthesis, they were able to modify
natural products with an aim to improve the selectivity,
potency, stability, and pharmacokinetics. Structure–activity
relationship (SAR) properties were investigated by semisyn-
thesis or fragment exchange of natural products, which led to
crucial discoveries.
A prime example in this regard has been the development
of statins for the treatment of cardiovascular disease, still the
leading cause of death worldwide. Although the first gen-
eration compounds introduced into the clinic were either
identical or closely related to a natural product (lovastatin),
the recognition of the crucial 3,5-dihydroxypentanoate scaf-
fold and optimization by medicinal chemistry led to much
more improved derivatives, which had a dramatic impact on
medicine and society (Figure 1).[1] More stringent criteria of
“drug likeness” following LipinskiÏs “rule of five” and related
ADME/pharmacokinetic criteria (ADME= adsorbtion, dis-
tribution, metabolism, excretion), along with the introduction
of high-throughput screening (HTS), led to a phasing out of
natural products in the lead generation process in drug
discovery in the late 1990s. However, in the past 25 years, this
paradigm pendent on combinatorial chemistry for medicinal
chemistry research has barely provided sufficient numbers of
innovative and effective new drugs in Pharma R&D. Inter-
estingly, half of all the new chemical entities (NCEs)
introduced over the last 30 years (540 out of 1073) were
based on natural products, which underlines their importance
for lead generation.[2]
Over the last decade, natural products have been expe-
riencing a renaissance in drug discovery; this is based on
a number of reasons, in addition to the statistics regarding
NCEs presented above. Many studies have revealed striking
differences between natural and synthetic compounds, with
Natural products have had an immense influence on science and have
directly led to the introduction of many drugs. Organic chemistry, and
its unique ability to tailor natural products through synthesis, provides
an extraordinary approach to unlock the full potential of natural
products. In this Review, an approach based on natural product
derived fragments is presented that can successfully address some of
the current challenges in drug discovery. These fragments often display
significantly reduced molecular weights, reduced structural
complexity, a reduced number of synthetic steps, while retaining or
even improving key biological parameters such as potency or selec-
tivity. Examples from various stages of the drug development process
up to the clinic are presented. In addition, this process can be leveraged
by recent developments such as genome mining, antibody–drug
conjugates, and computational approaches. All these concepts have the
potential to identify the next generation of drug candidates inspired by
natural products.
From the Contents
1. Introduction 3883
2. Natural Product Derived
Fragments in Drug Discovery 3884
3. Additional Sources of Natural
Product Fragment Lead
Structures 3896
4. Summary and Outlook 3897
Figure 1. Development of HMG-CoA reductase inhibitors for the treat-
ment of cardiovascular disease. CoA=coenzyme A, HMG=3-hydroxy-
3-methylglutaryl.
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the former being less hydrophobic, having more stereogenic
centers, a larger fraction of sp3-hybridized carbon atoms, more
O and less N, S, and halogen atoms, fewer rotatable bonds,
more fused, bridge, or spiro rings, and more solvated hydro-
gen bond donors and acceptors.[3] After all, these compounds
produced by nature are a result of millions of years of
evolutionary selection and are, hence, biologically prevali-
dated. All these factors have led to the validation of natural
products as prime starting points for drug discovery.
One of the main factors often negatively associated with
natural products as lead structures constitutes their limited
chemical tractability. The above-mentioned complex archi-
tecture, which sometimes requires lengthy synthetic
approaches, often disfavors selection of natural products for
further study in a research environment that is heavily under
pressure in terms of time and financial constraints. It is the
goal of this Review to showcase with several examples from
early development to the clinic that the structural complexity
of natural products can be reduced by the chemical synthesis
of smaller fragments (“less is more”, “reduce to the max-
imum”), while retaining (or sometimes improving) desired
biological parameters such as potency or selectivity. This
Review is not aimed at being comprehensive,[4] but instead
should guide the reader through successful design principles
and compounds that are at various stages of the development
process, from lead structure identification to the clinic. The
ultimate goal is shared or complemented by approaches such
as “diverted total synthesis”, “chemical or molecular edit-
ing”,[5] and “function-oriented synthesis” (FOS).[4a,6]
These approaches all present a unique opportunity of
retaining desired effects in minimized, biologically active
scaffolds as a consequence of “fragment likeness” with a high
degree of three dimensional similarity, yet overcome the
limitations of parent natural product structures, such as lack
of accessibility or viable synthetic approachability. In addi-
tion, these natural product derived fragments could add to the
discovery process in the context of fragment-based drug
discovery.[7]
2. Natural Product Derived Fragments in Drug
Discovery
2.1. Anticancer Activity
2.1.1. From Halichondrin B to Eribulin
The polyether macrolide halichondrin B[8] was reported in
1986 by Hirata and Uemura (Figure 2).[9] It was isolated from
the marine sponge Halichondria okadai Kadota, which had
been collected off the coast of Japan in the Western Pacific.
Later in 1991, Pettit et al. also isolated halichondrin B from
an Axinella sp. sponge, collected in Palau.[10] This marine
macrolide showed potent activity against B16 melanoma cells
(IC50= 0.093 ngmL
¢1) and powerful in vivo inhibition of
tumor growth (T/C)[11] in mice (in up to 375% of the test
group) over the control group and increased the mean
survival times for groups with murine B16 melanoma, P388
leukemia, and l1210 leukemia.[9b] Later studies revealed that
halichondrin B acts as a tubulin-destabilizing agent with
a slightly different mechanism of action from other antimi-
totics, such as the vinca alkaloids.[8a, 12] More specifically, it
inhibits tubulin polymerization and microtubule assembly,
tubulin-dependent GTP hydrolysis, nucleotide exchange on
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Figure 2. Structural comparison between halichondrin B and eribulin/
E7389. FDA=U.S. Food and Drug Administration.
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tubulin, and acts as a noncompetitive inhibitor of
the binding of radiolabeled vinblastine to tubu-
lin.[8a,12]
Despite this phenomenal biological activity, the
limited supply (less than 2 × 10¢6 wt% yield)[9b] of
the natural product from its marine source and the
potential for contamination with other closely
related halichondrins or highly toxic metabolites,
such as okadaic acid,[12] remained serious obstacles
that could only seemingly be circumvented by total
synthesis. Furthermore, the amount of material
needed to support preclinical development and
subsequent clinical trials was estimated to be
approximately 10 g.[8a,13] If found to be successful,
1–5 kgyear¢1 would be necessary to meet commer-
cial needs. Although the initial aquaculture with
Lissodendoryx sp. seemed promising, the ability of
scale-up to satisfy the commercial demands in
a reliable manner could not be achieved.[8a, 13]
Kishi and co-workers reported the first total
synthesis of halichondrin B, along with norhalichon-
drin B, in 1992.[8a, 14] The route relied on a series of
robust Nozaki–Hiyama–Kishi (NHK) reactions,
which were used to construct five key bonds in the
synthesis.[8a,14a,d,e, 15] Further improvements were
later developed,[16] but the optimized synthetic
route contained nearly 120 steps. Despite this, the
completion of this landmark total synthesis con-
vinced the U.S. National Cancer Institute (NCI) to
move halichondrin B into preclinical development
in March 1992.[13c] The Eisai Research Institute
initiated in vitro and in vivo studies of synthetic
halichondrin B, along with several analogues pro-
vided by the Kishi research group at Harvard
University.[17] Surprisingly, they found that the C1–
C38 macrolide, or the “eastern portion” of the
molecule, demonstrated activities within an order of
magnitude of the parent compound during an
in vivo 3–4 day growth inhibition assay with a DLD-
1 human colon cancer cell line (Figure 2).[8a, 18] They found
that themacrolactone could be replaced by a nonhydrolyzable
ester bioisostere to prevent susceptibility toward nonspecific
esterases. Attempts to truncate further while retaining
activity were unsuccessful. For example, the 2,6,9-
trioxatricyclo[3.3.2.0]decane was essential for the activity
and global conformation of the molecule.[9b]
Despite the success with total synthesis, the limited supply
of halichondrin B was a critical issue in the early 1990s, which
was eased, in particular, by the discovery of the potency of
simplified analogue eribulin, or E7389 (Figure 2).[18a] In
addition to the synthetic efforts by the Kishi group,[19] the
synthesis of the C14–C35 fragment (13) of eribulin
(Scheme 2) has been optimized for process development on
a kilogram scale. This most recent route put forth by Eisai Inc.
in 2013 begins with conversion of dihydrofuran (1) into C14–
C19 fragment 3, through a tin-mediated bromoallylation with
2,3-bromopropene (2 ; Scheme 1).[20] Fragment C20–C26 (5)
was synthesized from 1,2-epoxyhex-5-ene (4) in seven steps
by a hydrolytic kinetic resolution (HKR) with a Jacobsen
catalyst.[21]Aldehyde 5 and fragment 3 were then combined in
an asymmetric NHK Ni/Cr coupling with chiral ligand 6a,[22]
followed by treatment with silica gel to induce formation of
the tetrahydrofuran ring. Elaboration of furan 7 through six
steps provided the C14–C26 fragment 8. Synthesis of the C27–
35 fragment 12 commenced with transformation of readily
available d-glucurono-3,6-lactone (9) into C34–C35 diol 10 in
eight steps. Reaction of the tetrahydrofuran ring with
allyltrimethylsilane, followed by a Horner–Wadsworth–
Emmons olefination and a hydroxy-directed conjugate reduc-
tion afforded sulfone 11. Six additional steps provided the
desired C27–35 fragment 12 in a final yield of 26% through
an entirely chromatography-free, 20-step process.
The C14–C26 (8) and C27–C35 (12) subunits were
combined in an iterative Nozaki–Hiyama–Kishi reaction
and Williamson ether cyclization with ligand 6b (Scheme 1)
in d.r.= 20:1 and a 65% overall yield. A subsequent reductive
cleavage afforded the C14–C35 fragment 13 (Scheme 2).[23]
Sulfone 13 was then combined with the C1–C13 aldehyde 14
from the halichondrin B synthesis, which was assembled in
13 steps from l-mannonic-g-lactone.[16b] A SmI2-mediated
Scheme 1. Synthesis of the C14–C26 fragment 8 and C27–C35 fragment 12 of
eribulin by Kishi and co-workers. Bn=benzyl, Bz=benzoyl, DMAP=4-dimethyl-
aminopyridine, HMDS=hexamethyldisilazide, Ms=mesyl or methanesulfonyl,
NMM=N-methylmorpholine, Piv=pivaloyl, TBDPS= tert-butyldiphenylsilyl,
Tf= trifluloromethanesulfonyl, TMS= trimethylsilyl.
Angewandte
ChemieReviews
3885Angew. Chem. Int. Ed. 2016, 55, 3882 – 3902 Ó 2016 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
desulfonylation, a key Nozaki–Hiyama–Kishi macrocycliza-
tion, followed by oxidation were then performed. The
trioxatricyclo[3.3.2.0]decane ring system was installed in
macrocycle 15 in 90% yield by treatment with TBAF and
then PpTs. A subsequent transformation of the C35 hydroxy
group gave the amine of eribulin (16), which was optimized by
Kaburagi and Kishi in 2007 to an 84% overall yield.[24]
Additionally, the Kishi group reported a special system for
the formation of the trioxatricyclo[3.3.2.0]decane ring system,
which involved a DOWEX 50WX8-400 sulfonic acid resin
and CaCO3 work-up of the TBAF-mediated TBS cleavage
reaction, followed by filtration and evaporation.[25] Then,
passage of the resulting residue through an ion-exchange
resin-based device completed the formation of the ketal[16e] in
90% overall yield.[26]
In vivo studies revealed that eribulin possesses excellent
activities at 0.1–1 mgkg¢1 against several chemoresistant
human solid tumor xenografts.[18a] Eribulin displayed superior
efficacy over other antimitotics such as even paclitaxel.[13c]
These studies also confirmed that this analogue could induce
G2-M cell-cycle arrest and disrupt mitotic spindles, and was
consistent with the tubulin-based antimitotic mechanism of
the parent halichondrin B. Eisai investigated the safety and
effectiveness of eribulin mesylate in a single phase III clinical
trial involving 762 women with metastatic breast cancer,
during which the median overall survival of patients receiving
eribulin mesylate was 13.1 months, whereas this rate was
10.6 months for those receiving only a single agent therapy.[27]
The U.S. FDA approved eribulin mesylate (Halaven) on
November 15, 2010 for patients with metastatic breast cancer,
who have received at least two prior chemotherapy treat-
ments for late-stage disease, including anthracycline- and
taxane-based therapies. The European Commission has
recently followed suit, issuing their approval on July 3, 2014
under the same conditions as the FDA.[28] With this
approval in the European Union member states,
eribulin mesylate is now approved in more than
50 countries worldwide, including Japan, Singapore,
and Switzerland. Eisai is currently investigating
eribulin mesylate as a treatment for breast cancer
with fewer prior treatments, as well as soft-tissue
sarcoma and non-small-cell lung cancer.
Overall, the development of eribulin constitutes
a vast improvement over the parent compound as it
has a large decrease in complexity, including a 35%
reduction in molecular weight, which requires half
the number of synthetic steps to access, and retains
the potent antitumor activity, as clearly evident by its
use today as a cancer treatment agent worldwide.
2.1.2. From Migrastatin to a Core Analogue
Migrastatin was isolated in 2000 by the Imoto
group from a cultured broth of Streptomyces sp.
MK929-43F1 (Figure 3).[29] This 14-membered mac-
rolide with a glutarimide-terminated side chain
inhibited the spontaneous migration of EC17
human esophageal and B16 mouse melanoma cells
at a concentration of 10–30 mgmL¢1 (IC50=
82 mgmL¢1).[29c]
However, the compound demonstrated no appreciable
cytotoxicity, inhibition of protein synthesis, or antibiotic/
antifungal activities. In a follow-up study, the ability of
migrastatin to inhibit the growth of Ms-1 human small cell
lung carcinoma cells under anchorage-independent condi-
tions in a dose-dependent manner (1–100 mgmL¢1) implied its
influence on integrin signaling, which is also involved in cell
migration.[29c] A year after the absolute configuration was
confirmed by X-ray crystallography,[30] the Danishefsky group
reported the first synthesis of the macrolide by utilizing
a Lewis acid catalyzed diene aldehyde condensation
(LACDAC) and ring-closing metathesis (RCM).[31]
Follow-up SAR investigations by the Danishefsky group
revealed that, out of eight analogues screened, the migrastatin
Scheme 2. Completion of the synthesis of eribulin (16). Coll.=2,4,6-collidine or
2,4,6-trimethylpyridine, DIBAL-H=diisobutylaluminum hydride, DMP=Dess
Martin periodinane, Imid.= imidazole, PpTs=pyridinium para-toluenesulfonate,
TBAF= tetrabutylammonium fluoride, TBS= tert-butyldimethylsilyl.
Figure 3. Structural comparison between migrastatin and the migrasta-
tin core analogue. IC50 values are for 4T1 murine breast cancer.
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core surpassed the activity of the parent compound
in a Boyden chamber cell migration assay with
serum-induced 4T1 mouse breast tumor cells by
three orders of magnitude, with an IC50 value of
22 nmolL¢1, versus the 29 mmolL¢1 value for migras-
tatin (Figure 4).[32a] Analysis of other analogues
revealed that reduction of the C2¢C3 double bond
could be tolerated, while modification of the hy-
droxy group at C9 or at C13, or at the ketone at C1
could not be tolerated with respect to the potent cell
migration suppression activity.[31c] Eight analogues
and migrastatin were also tested for their metabolic
stability in mouse plasma and, while the parent
compound and compounds containing a glutarimide
side chain were inert, the most active compounds
including the migrastatin core analogue were hydro-
lyzed rapidly by esterases. These findings resulted in
the macrolactam and macroketone analogues being
lead compounds from these studies, with IC50 values
of 255 nmolL¢1 and 100 nmolL¢1, respectively, and
with no esterase susceptibility.[34a] As it was sus-
pected that these analogues influence the angio-
genesis process, Danishefsky and co-workers also
investigated endothelial cell migration with human
umbilical vein endothelial cells (HUVECs). These
results mirrored the previous ones, in that the
analogues showed more activity than the parent compound,
albeit with some erosion of potency, and they found that the
macrolactam, macroketone, and the macrolactone analogues
did not have any cytotoxic or antiproliferative effects up to
20 mmolL¢1 in an in vitro mouse assay.[32a] This observation
confirmed that inhibition of cell proliferation is not a contrib-
utor to the effects observed in the chamber assays. A year
later in 2005, Danishefsky and co-workers reported that
several analogues, including the migrastatin macrolactam
analogue, inhibit mammary tumor metastasis in mice, which
suggests that these compounds interfere with the invasion
step by demonstrating that they block Rac activation,
lamellipodia formation, and cell migration.[34]
In a 2010 report, the Danishefsky group reported an even
more simple, new macroether (ME) analogue 23 that retains
the cancer cell migration inhibition activity of the analogue
family (Scheme 3).[32b] The synthetic sequence towards ME
analogue 23 shared the first nine steps of the original route
towards the natural product.[31a–c] The synthesis began with
transformation of tartrate derivative 17 into aldehyde 18 by
utilizing a highly diastereoselective divinylzinc addition. The
key LACDAC reaction of aldehyde 18 with diene 19 was
performed under a-chelation control in the presence of the
Lewis acid TiCl4, and then cyclization with TFA proceeded in
87% yield to afford dihydropyranone 20. Selective 1,2-
reduction of the ketone and treatment with CSA promoted
a Ferrier rearrangement to the corresponding lactol 21, which
was then transformed into primary alcohol 22 in three steps. A
Williamson etherification reaction and RCM afforded ME
analogue 23 in 47% yield over the five steps. Overall, this
analogue had a significant reduction in the complexity of
migrastatin, yet retained the activity of the parent compound,
and was accessed in 11 fewer synthetic steps.
In cell-migration assays, ME analogue 23 demonstrated
migration inhibition against several breast cancer cell lines,
including the highly metastatic human LM2, without affecting
Figure 4. Comparison of the structures and activities of migrastatin
analogues from chamber cell migration assays. IC50 values in paranthe-
ses are with the following cell lines: [a] 4T1 murine breast cancer,[31c, 32]
[b] HUVEC human umbilical vein endothelial cells,[31c] and [c] A549
human lung cancer.[33]
Scheme 3. Synthesis of the migrastatin macroether analogue by Danishefsky and
co-workers (ME, 23). CSA=camphorsulfonic acid, DCM=dichlormethane, 2,6-
Lut.=2,6-lutidine, pyr=pyridine, TBAI= tetrabutylammonium iodide, TFA= tri-
fluoroacetic acid, TBSOTf= tert-butyldimethylsilyltrifluoromethane sulfonate.
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the viability of the cells.[32b] This analogue also inhibited
tumor invasion and metathesis, and prolonged the
overall survival in NOD/SCID mice injected with
human breast cancer MDA-MD-231 cells in the
abdominal mammary fat pad (human breast cancer
xenograft model).[33] In the course of these studies, the
authors also proposed that 23 interferes with fascin-1-
dependent migratory behavior. This interaction was
confirmed by Chen et al. in 2010 with the X-ray crystal
structure of the macroketone analogue in actin-binding
sites of fascin.[35] However, there was some debate over
this result, as the X-ray structure of the macroketone
analogue contained an E- instead of the Z-configured
double bond between C4 and C5, and the C6 stereo-
center was inverted to the S configuration.[36]
In 2011, Danishefsky and co-workers reported that
23was considered to be the most promising analogue on
the basis of its in vitro and in vivo activities, physical
properties, ease of preparation, and biological stability
(Figure 4).[33] This publication details the promising in vitro
and in vivo migration inhibition activity of ME against
metastatic small-cell lung carcinoma (SCLC), and also
introduced yet another promising candidate, carboxymethyl-
ME (CME), which was synthesized with an aim to enhance
the bioavailability and pharmacostability, and achieved
a higher potency with lower toxicity than ME. This CME
analogue was also used as evidence against the X-ray
crystallography studies of Chen et al.: since the carboxylic
acid functionality reduced cell membrane permeability, and
this compound retained its potent metastasis inhibition, the
findings implied that the primary target is not an intracellular
protein such as Fascin, but a protein target on the cell surface.
In 2013, Majchrzak et al. added to this debate by reporting
that the migrastatin core analogue showed antibranching
activity and interfered with the mechanisms of filopdia
assembly, thereby preventing cross-linking of fascin-1-depen-
dent actin filaments in vitro.[37] Overexpression of fascin1 in
cancer cells has been linked with clinically aggressive tumors,
poor prognosis, and shortened disease-free survival. Further
studies on these migrastatin analogues and additional struc-
tures are ongoing.
2.1.3. From Anguinomycin C/D to an Anguinomycin Analogue
In 1995, Hayakawa et al. reported the structures of
anguinomycins C and D, which were isolated from cultures
of Streptomyces sp. (Figure 5).[38] These antitumor antibiotics
induced cell death in pRB-inactivated glia cells at picomolar
concentrations and, surprisingly, cell-cycle arrest at only the
G1 phase was observed for normal rat glia cells. Retinoblas-
toma tumor suppressor protein (pRB) is often inactivated
during the development of a variety of cancers.
The absolute configuration of anguinomycin C was con-
firmed by the first total synthesis in 2007 by Gademann and
co-workers. This route had a total of 29 steps, with 18 steps in
the longest linear sequence, and an overall yield of 6.7%.[39]
Biological studies demonstrated that this natural product is
a potent inhibitor of CRM1-dependent protein export from
the cell nucleus, an activity shared by a close structural
relative, leptomycin B. It is known that leptomycin B cova-
lently modifies chromosomal region maintenance 1 (CRM1;
exportin 1) at the nucleophillic sulphydryl group of Cys528 by
utilizing its a,b-unsaturated d-lactone, thus preventing export
of protein cargoes that rely on this cleft by preventing
formation of the ternary CRM1/cargo substrate/Ran com-
plex, or the binary complex CRM1/cargo substrate in the
absence of Ran.[40] More recent computational studies of
inhibitors, such as leptomycin B, to CRM1 revealed that the
mechanism of inhibition goes beyond simple Michael addi-
tion, and is followed by a CRM1-mediated hydrolysis of the
lactone.[41] Mutagenesis revealed that at least one of the
residues Arg543, Lys548, or Cys579 needs to be present to
stabilize the resulting anionic tetrahedral intermediate and
lower the energy barrier to drive the reaction. Furthermore,
evidence not only supported that hydrolysis must follow
conjugate addition, as the corresponding hydroxy acids do not
inhibit CRM1, but also that hydrolysis decreases the rever-
sibility of the Michael addition and enables persistent binding
of the inhibitors to CRM1. This argument is supported by the
fact that reversibility of the conjugate addition should be
kinetically controlled and the a-proton of the hydrolyzed
(carboxylate) intermediate is much less acidic than the
corresponding proton of the lactone.[41]
Although dose-limiting toxicity prevented further devel-
opment of leptomycin B as an antitumor agent,[42] Gademann
and co-workers saw the potential of the anguinomycin core
and went on to synthesize anguinoymcin D and analogues for
further studies with the aim of investigating if the polyketide
side chain mimics the hydrophobic leucine-rich nuclear
export signal of the cargo protein and is necessary for
activity.[43] The route employed was similar to the synthesis of
the anguinomycin C derivative, and began with an asymmet-
ric hetero-Diels–Alder reaction between diene 24 and
aldehyde 25 with catalyst 26 according to Jacobsen et al.,[44]
which afforded pyran 27 in 86% yield and with 96% ee
(Scheme 4). The acetal was inverted to the more thermody-
namically stable compound and a hydrozirconation of the
alkyne with the Schwartz reagent, followed by transmetala-
tion with Zn for a Negishi cross-coupling utilizing [PdCl2-
Figure 5. Structural comparison between anguinomycin C/D and the anguino-
mycin D analogue.
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(DPEphos)] with dibromoolefin 28[45] to afford diene 29, but
with inversion to the undesired isomer. Inversion to the
desired Z olefin was accomplished with another Negishi
cross-coupling reaction to install the ethyl group in 84%
yield and with good selectivity. Silyl ether 30 was then
converted into boronate 31. A classic, Evans syn-aldol
strategy was employed to assemble vinyl iodide 33 with the
DIOZ (4-isopropyl-5,5-diphenyloxazolidin-2-one) auxiliary
32 developed by Hintermann and Seebach.[46] The 13 step
route, which was executed in 24% overall yield, employed the
DIOZ auxiliary three times and two boron-mediated aldol
reactions. Boronate 31 and vinyl iodide 33 were combined
under Suzuki coupling conditions developed by Marshall
et al.[47] With a particular batch of the Suzuki
reaction, there was a minor by-product, which was
taken with desired product 34 through the last three
steps and purified by column chromatography to
afford not only anguinomycin D (35), but also
aldehyde analogue 36 and truncated analogue 37,
likely a degradation product of the boronate
intermediate from the previous Suzuki coupling.
These compounds were then screened for their
ability to inhibit CRM1-dependent protein export
by measuring the accumulation of Rio2 protein in
the HeLa cell nucleus by indirect immunofluores-
cence analysis. Anguinomycin C and D (Figure 5)
both displayed partial inhibition at 5 nmolL¢1 and
full inhibition at 10 nmolL¢1 while, surprisingly,
aldehyde analogue 36 showed full inhibition at
50 nmolL¢1 and truncated analogue 37 exhibited an
unexpected strong inhibition at 25 nmolL¢1. This
study demonstrated that the activity could be
retained even when the anguinomycin polyketide
chain was replaced by a hydrophobic moiety or
when completely removed, and reinforced the
importance of the conjugate acceptor ability of
the a,b-unsaturated d-lactone.[41] This concept that
the anguinomycin core could be reduced by nearly
60% in molecular weight and still retain its activity
was supported by molecular modeling studies of the
(R)-a,b-unsaturated d-lactone in the NES (nuclear
export signals) binding pocket of CRM1[40c–e] with
all-atom energy minimization (Figure 6).[49] Further
investigations into this more synthetically accessi-
ble, truncated analogue 37 of anguinomycin could
provide more powerful or selective nucleocytoplas-
mic transport inhibitors for cancer treatment.[50]
2.1.4. From Duocarmycin SA to N-Boc-DSA
Duocarmycin SA was isolated from Streptomy-
ces sp. DO113 collected from a soil sample at the
Rokkakudo temple in Kyoto, Japan in 1990 by
Takahashi and co-workers, and given its name
because it was more stable and demonstrated
more potent Gram-positive antibacterial (minimum
inhibition concentrations (MICs): 2.7 nmolL¢1 for
Staphylococcus aureus and 1.4 nmolL¢1 forBacillus
subtilis) and cytotoxic activities (against murine
lymphocytic leukemia P388 and murine sarcoma 180) than
close relative duocarmycin A (Figure 7).[51] The duocarmycins
act as sequence-selective DNA alkylating agents with 3’!5’
binding directionality, specific for AT-rich regions in the
minor groove, where stabilizing van der Waals contacts are
maximized.[52] Binding of the agent to DNA induces a con-
formational change, which disrupts the stabilization of the
vinylogous amide and activates the cyclopropane ring of the
cyclopropapyrroloindole in the left-hand side of the core for
the reversible, stereoelectronically controlled adenine-N3
addition in an SN2 fashion (shape-dependent catalysis).
[52b]
The bound agent spans 3.5 base pairs and complements the
topological curvature and pitch of the minor groove, with the
Scheme 4. Synthesis of anguinomycin D (35) and analogues by Gademann and co-
workers. Cp=C5H5, DPEphos=bis[(2-diphenylphosphino)phenyl]ether, dppf=1,1’-
bis(diphenylphosphino)ferrocene, 9-methoxy-BBN=9-methoxy-9-borabicyclo-
[3.3.1]nonane, PCC=pyridinium chlorochromate, TES= triethylsilyl, TIPS= triiso-
propylsilyl, TsOH=p-toluenesulfonic acid.
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hydrophobic face of the molecule implanted deeply within.[53]
SAR studies of another close relative, (+)-CC-1065, identi-
fied the required, but not necessarily optimal, pharmacophore
for this family of molecules, thus rendering further studies on
the more active and stable duocarmycin SA necessary.
The first total synthesis of duocarmycin SA (46), as well as
the synthesis of analogue 44 was reported in 1992 by Boger
and Machiya (Scheme 5).[54] Two successive regioselective
alkylations of substituted diimide quinone 39 (synthesized in
5 steps and 38% yield)[55]were performed at C5 with dimethyl
malonate (38), and then at C6 with pyrrolidine enamine of
pyruvaldehyde dimethyl acetal 40[56] to afford aniline 41.
Acidic conditions removed the acetal group and promoted
indole formation, which was followed by cyclization of the
resulting diol to complete the dihydropyrroloindole core 42.
Eight additional steps, including chiral resolution of the bis-
(R)-O-acetylmandelate esters, provided (+)-dihydropyrro-
loindole 43. This intermediate could then be directly trans-
formed into (+)-N-Boc-DSA analogue 44 in 85% yield, or to
the natural antipode of (+)-duocarmycin SA (46) by coupling
with the 5,6,7-trimethoxyindole-2-carboxyclic acid salt 45
(made in 3 steps and 74% yield from 3,4,5-trimethoxyben-
zaldehyde)[53] in 53% yield over the two steps. The unnatural
(¢)-N-Boc-DSA and (¢)-duocarmycin SA enantiomers were
also synthesized from (¢)-ent-43.
The natural (+)-enantiomers were found to have 10 times
more potent in vitro cytotoxicity than the corresponding
unnatural (¢) enantiomers, with IC50 values (L1210 mouse
lymphocytic leukemia) of 10 pmolL¢1 for (+)-duocarmy-
cin SA and 6 nmolL¢1 for (+)-N-Boc-DSA.[54b] N-Boc-DSA
was found to be a substantially less efficient (ca. 104 times)
DNA alkylator, with a less strict selectivity profile than the
parent natural product (SA), and with both enantiomers
showing the same site reactivity profile.[52a] The latter
property was also unusual, but a natural consequence of the
diastereomeric relationship of the adducts. N-Boc-DSA was
found to be the most stable of the duocarmycin analogues, as
measured by chemical solvolysis, with complete stability at
pH 7 and a half-life of 177 h at pH 3.[54b] Gas-phase heats of
reaction for the alkylation of N-methyladenine with N-
acetylduocarmycin A and N-acetylduocarmycin SAwere cal-
culated by using semiempirical methods (AM1, MNDO). The
results reflected the experimental observations that the
alkylation of DNA is reversible (unlike with (+)-CC-1065),
as the model calculations with methyladenine gave a near
thermally neutral reaction.[54b] This underlines the importance
of noncovalent interactions in the minor groove
(hydrophobic binding/van der Waals contacts), as
DNA is nonetheless effectively alkylated by duocar-
mycins (binding-driven bonding).
A fundamental parabolic relationship for all the
duocarmycins was established between the reactivity
of the electrophilic cyclopropane ring and the
cytotoxic activity spanning a 104–106 range, where
an increased solvolytic stability or decreased reac-
tivity correlates to an increased cytotoxic poten-
cy.[54b,57] Highly stable analogues do not efficiently
alkylate the DNA, while highly reactive analogues do
not reach the biological target. For proof of concept,
Boger and co-workers introduced the rationally
designed thiophene analogue N-Boc-MeCTI in
2007, which reflected the optimal point of balanced
stability and reactivity in the parabolic relationship,
being slightly more stable, but 5–6 times less potent
than N-Boc-DSA (Figure 7).[57,58] In this study, they
also reported analogue MeCTI-TMI, which has an
even higher cytotoxic potency than duocarmycin SA
(IC50= 5 pmolL
¢1 versus 10 pmolL¢1). The retained
single-digit nanomolar potency of N-Boc-DSA
despite a significant reduction in structural complex-
ity rendered it an excellent example of capturing
biological activity with a natural product fragment.
Figure 6. Computational model of A) leptomycin B and B) truncated
analogue 37 binding to CRM1 (C: gray, O: red, N: blue; C in inhibitor
molecule: yellow).[48]
Scheme 5. Total synthesis of (+)-duocarmycin SA (46) and (+)-N-Boc-DSA (44)
by Machiya and Boger. DEAD=diethyl azodicarboxylate, EDCI=1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide, DSA=duocarmycin SA.
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2.1.5. From Dynemicin A to a Dynemicin Analogue
The violet dynemicin A was discovered in 1989 in the
fermentation broth of Micromonospora chersina sp. (M956-
1), isolated from a soil sample from Gujarat State, India
(Figure 8).[59] It demonstrated potent Gram-positive antibac-
terial activity with low toxicity, especially against Staph-
ylococcus aureus Smith infection (mouse i.p., PD50=
0.13 mgkg¢1), and potent in vivo antitumor activity against
B16 melanoma, Moser human carcinoma, HCT-116 human
carcinoma, and normal/vincristine-resistant P388 leukemia
(IC50= 7–9 nmolL
¢1), even prolonging the life span of mice
with P388 leukemia or B16 melanoma. Structurally, it
contains a unique hybrid of an anthraquinone and a 1,5-
diyn-3-ene system embedded within a strained 10-membered
ring. The enediyne unit makes it a relative of the esperamicin/
calicheamicin family. The mechanism of action involves
intercalation of the anthraquinone core of into the minor
groove of the DNA helix, followed by attack of the phenyl
diradical resulting from the enediyne core, thereby leading to
DNA strand scission of the sugar–phosphate backbone three
base-pairs apart.[60] The phenyl diradical is proposed
to form by two sequential one-electron reductions of
the hydroquinone to the hydroquinonediol, epoxide
opening (key to activation), nucleophilic attack (i.e.
water) on the p-quinone methide intermediate or
simple tautomerization, and then Bergman cycliza-
tion of the strained (Z)-enediyne to the diaryl radical.
Dynemicin A preferentially cuts the 3’ side of purine
bases with a preference for guanines, thus differing
from its esperamicin/calicheamicin relatives, and
demonstrates a preference for double-stranded (B-
form) and stem regions of single-stranded DNA.
Along with several pioneering synthetic stud-
ies,[61] the first total synthesis and absolute config-
uration of (+)-dynemicin A was reported by Myers
et al. in 1995.[62] In total, this route was completed in
26 steps in 0.3% yield and employed an exo-selective
Diels–Alder reaction as the key step. Several ana-
logues were also made by using the same approach. In the
following years, copious synthetic and SAR studies of
enediyne analogues of the dynemicin core were performed
by the groups of Schreiber,[61a,d] Wender,[63] Nicolaou,[61b,64]
Isobe,[65] Myers,[62a,66] Danishefsky,[61g,67] Maier,[68] Magnus,[69]
and others.[64a,d,70] These studies probed the effects of trigger-
ing groups or initiators on the nitrogen atom or aryl ring,
which could be activated under basic or photochemical
conditions that could be mimicked by intracellular
processes. Tethering devices were also investigated to
aid target delivery, as were deactivating groups that
would modulate enediyne activity, as well as detection
devices that would facilitate mechanistic studies.[64a]
One of the most potent dynemicin analogues was the
sulfone analogue of Nicolaou et al. with an IC50 value
of 20 fm against Molt-4 T-cell leukemia, as compared
to an IC50 range of 0.1 nmolL
¢1-0.1 mmolL¢1 for dyne-
micin A (Figure 8)[64a,b,d,71] However, one of the most
simplified analogues was accessed by Wender et al. in
just 7 steps (Scheme 6).[63a] The route began with the
reduction of commercially available quinoline carbox-
yaldehyde (47) and then stepwise incorporation of the
enediyne bridge, first by ethynyl Grignard addition to
the imine to give alkyne 48, followed by formation of
the key epoxide and Sonogashira coupling with enyne
49. Oxidation of alcohol 50 to the aldehyde and
treatment with cesium fluoride permitted closure of
the strained 10-membered ring, thereby producing
analogue 51. As compared to the parent compound, this
greatly simplified analogue exhibited the same activity profile
for cleaving plasmid DNA.[63b,d]
2.1.6. From Bryostatin 1 to Picolog
The bryostatin family consists of 20 complex natural
products that were isolated from the marine bryozoan
Bulgula neritina, starting in the late 1960s.[72] They all share
a 20-membered macrolide core with three densely substituted
tetrahydropyran rings and a signature exocyclic enoate
appended to at least one of these rings. The actual source of
these molecules has been narrowed down to a bacterial
Figure 8. Structural comparison of dynemicin A and analogues. IC50 values are
for Molt-4 T-cell leukemia.
Figure 7. Structural comparison of duocarmycin SA and analogues. IC50 values
are for L1210 mouse lymphocytic leukemia. Boc= tert-butoxycarbonyl, MeCTI=7-
methyl-1,2,8,8a-tetrahydrocyclopropa[c]thieno[3,2-e]indol-4-one, TMI=5,6,7-trime-
thoxyindole-2-carboxylate.
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symbiont of B. neritina, Endobugula sertula, which uses them
to protect its larvae from predators.[73] The most well-studied
member, bryostatin 1, has a diverse and extremely important
range of biological activities stemming from its ability to
modulate protein kinase C (PKC; Figure 9).[74] Bryostatin 1
exhibits potent anticancer activity by reversing drug resist-
ance, stimulating the immune system, or restoring apopotic
function.[75] It either has been or is currently being evaluated
in 37 clinical trials for various types of cancer.[76] It has also
been shown to enhance memory and learning in animals,
reduce Ab peptide build-up in mice, induce synaptic contact
formation, and reduce postischemic/hypoxic damage result-
ing from stroke.[77] As such, it has been evaluated in two
clinical trials for AlzheimerÏs disease, with another
trial currently ongoing. In addition, bryostatin 1 is
also currently being evaluated for HIV/AIDS treat-
ment in yet another clinical trial. A recent study
confirmed its ability to activate latent viral reservoirs
and downregulate the CD4 cell surface receptor
synthesis/expression necessary for viral entry into
uninfected cells.[78] Other potential therapeutic appli-
cations include treatments for cardiovascular disease,
stroke, pain, or cognitive dysfunction.
Despite the remarkable biological activity of the
bryostatins, the clinical supply by good manufacturing
practice (GMP) is dwindling because of the natural
scarcity (isolation yields of 1 × 10¢3 to 1 × 10¢8%), the
lack of sustainable success with aquaculture or
biosynthesis, and the lack of facile or scalable routes
to these molecules, notwithstanding the synthetic advances of
the last 30 years. Currently, seven total syntheses of bryosta-
tins 7, 2, 3, 16, 1, and 9 have been reported by the groups of
Masamune,[79] Evans,[80] Yamamura,[81] Trost,[82] Keck,[83]
Wender,[84] and Krische.[85] The initial routes were completed
in 79–89 steps, with the most recent route towards bryostatin 7
by Krische and co-workers in 2011 being the most
efficient with a total step count of 36 (longest linear
sequence: 20 steps).
In an effort to avoid stepwise limitations of total
synthesis, and the dose-limiting toxicities of the
parent compound, extensive studies on the synthesis
and evaluation of bryostatin analogues (bryologs)
have been performed, most comprehensively by the
Wender research group since the 1980s. To date, over
100 analogues have been synthesized and screened
for various activities, and nearly one-third exhibit
single-digit nanomolar or even picomolar potencies
for PKC binding.[6d] These studies were primarily
driven by the guiding principle that the bryostatin
core structure could be divided into the upper
“binding” or “recognition domain” (C1–C14) and
lower “spacer domain” (C15–C27) according to its
interactions with PKC (Figure 9).[86] Studies on
bryologs have examined the significance of the
A ring,[87] the B ring,[88] the C20[89] and C7 side
chains,[90] as well as de novo structures,[91] among
others.[92] Notable examples of analogues include
picolog synthesized by Wender et al. (reported in
2002 with a PKC binding affinity of 0.25 nmolL¢1),
which was synthesized in 29 steps with a longest
linear sequence of 19 steps.[93] This represented one
of the most potent and promising simplified bryo-
logs, as this was realized in 50 fewer synthetic steps
than the syntheses towards the parent structure at
that time, and surpassed its activity (bryostatin 1,
PKC Ki= 1.35 nmolL
¢1).
The synthesis of picolog (61) began with the conversion of
diol 52 into aldehyde 53 in four steps so that an asymmetric
Keck allylation could set the stereocenter at C23 and an acid-
catalyzed cyclization/dehydration could form lactone 54
(Scheme 7).[93b,c] An additional, straightforward seven steps
elaborated the pyran ring, including installation of the acyl
Figure 9. Structural comparison of bryostatin 1 to bryologs (LL= longest linear
sequence). [a] Protein kinase C rat brain mix.
Scheme 6. Synthesis of the dynemicin core analogue (51) by Wender and co-
workers. mCPBA=meta-chloroperbenzoic acid.
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octanoic acid side chain at C20, to give aldehyde
55. The enal was installed at C15 through a zinc-
mediated addition of (Z)-bromo-2-ethoxyethene,
followed by acid-induced elimination and then
Sharpless dihydroxylation, cleavage of the pyran
ketal, and protection with a silyl group gave
intermediate 56, precursor to the recognition
domain. The spacer domain 60was synthesized in
10 steps from 4-benzyloxy-2-butanone (57) and
methyl 5-chloro-5-oxovalerate (58) by employing
two asymmetric Noyori hydrogenations and
a dienolate addition of ethyl acetoacetate (59)
in between. The two domains were combined by
utilizing a PyBrop-mediated esterification and
a deprotection/macro-transacetalization step to
afford picolog (61) in a 63% yield over the two
steps.
As the original synthetic routes towards the
parent bryostatin compounds were limited by
a Julia olefination/lactonization sequence, the
groups of both Wender and Keck sought a new
approach and developed a Prins macrocycliza-
tion[94] as a key step in back-to-back reports in
2008 (Figure 9). This novel tactic allowed access
to more complex bryologs in fewer steps than the
parent compounds and with even higher potency
than picolog.[95] This same powerful strategy was
used by Wender and co-workers in 2012 to access
bryologs that demonstrated 1000-fold higher
potency than prostratin, the leading clinical candidate
at the time.[78b] More recent progress has culminated in
the Merle series of bryologs from Keck and co-work-
ers,[96] and the most simplified bryologs to-date from
Wender et al.—the salicylate-derived class (Figure 9).[97]
This bryolog shown can be accessed in only 23 steps and
displays nanomolar PKC binding affinities. The evolution
of the bryolog structures and their broad therapeutic
applications has been advancing now for more than
40 years and continues to provide a source of inspiration
for discovery.
2.2. Antibiotic Activity
2.2.1. From Caprazamycin B to an Oxazolidine analogue
Caprazamycin B (CPZ-B) was isolated in 2003 by
Igarashi et al. from the culture broth of the actinomycete,
Streptomyces sp. MK730-62F2 (Figure 10).[98] This anti-
microbial agent demonstrated excellent activity against
drug-susceptible and multidrug-resistant M. tuberculosis
(MDR-TB or XDR-TB), without significant toxicity in
mice. The caprazamycin family (CPZs) are part of the 6’-
N-alkyl-5’-b-O-aminoribosoyl-glycluridine class of anti-
biotics, and include liposidomycins (LPMs), which
exhibit excellent antimicrobial activities against Gram-
positive bacteria.[99] The mode of action of these lip-
onucleosides is inhibition of peptidoglycan synthesis by
Scheme 7. Synthesis of picolog (61) by Wender and co-workers. DIPEA=di-
isopropylethylamine, PyBrop=bromotripyrrolidinophosphonium hexafluoro-
phosphate.
Figure 10. Structural comparison of caprazamycin B and analogues. MIC values are
given against MDR-TB, XDR-TB, MRSA, and/or VRE strains. IC50 values are given for
MraY inhibition.
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inhibition of phospho-MurNAc-pentapeptide trans-
locase (MraY translocase I). MraY is essential for
bacterial cell growth, thus making it a target of
interest for the treatment of tuberculosis (TB),[100]
and even vancomycin- and methicillin-resistant
Staphylococcus aureus (VRSA, MRSA).[101]
Although a very promising antibacterial treat-
ment, CPZ-B has remained synthetically challenging,
especially in regard to attaching the unstable fatty
acid side chain. This fact, combined with an onerous
HPLC separation and a poor water-solubility profile,
has prevented it from becoming a therapeutically
viable candidate.[102] Only recently has a total syn-
thesis been reported for the less-active caprazamy-
cin A[103] by Takemoto and co-workers,[104] while
Watanabe and co-workers have reported a partial
synthesis of the western portion of CPZ-B.[105] Thus,
the primary focus over the years has been on
analogues of CPZ, developed primarily by Ichikawa,
Matsuda, and co-workers.[106] During their studies,
the potency of the diketopiperazine and acyclic analogues
revealed that the diazepanone moiety was not essential, but
contributory to antibacterial activity.[106b,107] Replacing the
diazepanone and aminoribose units with an oxazolidine
moiety restricted the flexibility sufficiently to lead to an
increase in potency of MIC= 2–16 mgmL¢1 against MRSA
and VRE (vancomycin-resistent enterococci) strains (oxazo-
lidine analogue; Figure 10).[107] The most recent studies
include CPZ analogues such as CPZEN-45 with particularly
high potency against MDR-TB strains.[102] As the oxazolidine
analogues were revealed to be weak MraY inhibitors
(IC50= 920–1200 mm), Ichikawa et al. recently reported
the carbacaprazamycin analogues, with MIC values of
4–16 mgmL¢1 and MraY inhibition with IC50 values of
2.6–6.9 nmolL¢1.[108] However, the morphological
changes observed in S. aureus indicated a mode of
action that may be completely different from existing
peptidoglycan inhibitors.
The most potent oxazolidine analogue 65 can be
accessed in just 12 steps, starting with an oxidation, two-
carbon elongation, and an aminohydroxylation[109] of
uridine 62 to afford amino alcohol 63 (Scheme 8).[107]
Protecting group manipulations and installation of the
oxaziridine ring by condensation with azidoacetalde-
hyde, followed by acylation afforded N-palmitoyloxa-
zolidine 64.[107] Finally, conversion of the methyl ester
into the tert-butyl ester by using an isourea derivative
followed by reduction of the azide to the amine
afforded oxazolidine analogue 65. The overall reduc-
tion in the complexity of this analogue compared to the
parent compound is striking, all the while retaining its
potent antibiotic activity against multidrug-resistant
strains.
2.3. Neuritogenic Activity
2.3.1. From Militarinone D/Farinosone A to Pyridone Analogues
A plethora of biologically active pyridone alkaloids have
been isolated from entomopathogenic Deuteromycetes fungi.
Militarinone D was isolated in 2002[110] and later identified
together with several related molecules in 2003[111] by Ham-
burger and co-workers through bioassay-guided fractionation
of a mycelial extract of Paecilomyces militaris (RCEF 0095),
which displayed pronounced neuritogenic activity in PC-12
cells (Figure 11). Isolated from a mycelial extract of a related
fungus, farinosones A and B structurally resemble the mili-
tarinones, retain similar neurite outgrowth activity, and
exhibit no appreciable cytotoxicity.[112] A number of other
pyridone alkaloids have been synthesized and evaluated in
terms of their biological activity.[111,113]
In 2011, Gademann and co-workers developed a unified
approach toward several related pyridone alkaloid natural
Scheme 8. Synthesis of the oxazolidine analogue (65) by Ichikawa, Matsuda, and
co-workers. Cbz=benzyloxycarbonyl, (DHQD)2AQN=1,4-bis(dihydroquinidinyl)-
anthraquinone, IBX=2-iodoxybenzoic acid.
Figure 11. Structural comparison of militarinone D and farinosone A with
pyridone alkaloid analogues.
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products.[114] They found that these natural prod-
ucts, their enantiomers, and some additional iso-
mers with a Z-configured double bond in the side
chain demonstrated neuritogenic activity in
a standardized PC-12 assay, thereby revealing
that neither the length of the side chain nor the
absolute configuration were essential to the phar-
macophore of this molecule family. In 2013, the
Gademann group followed up with further SAR
studies and found truncated analogue 69 to have
a comparable neurite outgrowth capacity as far-
inosone A at 20 mm.[115] Easily synthesized by
utilizing the same general route as for the pyridone natural
products, pyridone analogue 69 was accessed in just seven
steps from ethyl cyanoacetate (66) and 12% overall yield by
utilizing a Suzuki–Miyaura coupling between the brominated
pyridone 67 and pinacol borane 68 (Scheme 9). The neurito-
genic effects of pyridone analogue 69 could even be observed
down to concentrations of 1 mm. Further investigations mir-
rored prior biological studies[116] and revealed that this potent
analogue, as well as militarinone D, influence theMAP kinase
pathway, as the neuritogenic effects could be blocked by co-
incubation with the ERK1/2 inhibitor PD98059 (at 5 mm).
Recently, Waldmann and co-workers reported a militarinone-
inspired collection of pyridones, and identified the stress
pathway kinase MAP4K4 as the target (Figure 11).[117] Both
examples show that by reducing the number of carbon atoms
by nearly a half, much more simplified, but still potent natural
product fragments could be successfully produced.
2.4. Miscellaneous Biological Activity
In addition to those presented within this Review, there
are many other notable examples of biologically active,
natural product derived fragments (Figure 12). Myers and
Herzon demonstrated that avrainvillamide had the same
nanomicromolar antiproliferative activity (IC50= 50–
100 nmolL¢1) against several cancer cell lines as its structural
dimer, stephacidin B.[118] These investigations, including SAR
Scheme 9. Synthesis of pyridone analogue 69 by Gademann and co-workers.
Pin=Pinacol, SEM= trimethylsilylethoxymethyl.
Figure 12. Structural comparison of additional natural product derived, biologically active fragments and their parent compounds.
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studies of several analogues, established the absolute stereo-
chemical configuration, found that this reversible dimeriza-
tion occurs through the 3-alkylidene-3H-indole 1-oxide func-
tional group, attributed the activity of stephacidin B to arise
from dissociation to avrainvillamide (as hypothesized), and
identified the nucleolar phosphoprotein nucleophosmin as
a biological target. The elegant studies of the well-known
antibiotic vancomycin and its aglycon by Crowley and Boger
found the simplified structure to have more potent activity
against a vancomycin-resistant strain than the parent com-
pound (mgmL¢1 versus mgmL¢1 activity).[119] These inves-
tigations reaffirmed the dimeric binding model[120] and
addressed the growing vancomycin-resistance issue. Another
example is the truncation of the 14-mer cyclic peptide
hormone somatostatin (SRIF14) to the 8-mer, octreotide.
[6c,121]
Now marketed by Novartis as the acetate salt, this drug is
70 times more potent than its parent peptide in vivo, and is
used in the treatment of acromegaly as well as symptoms
associated with metastatic carcinoid tumors or vasoactive
intestinal peptide-secreting adenomas. This example showed
that it is possible to mimic the activity of natural hormones
with a truncated, synthetic analogue, and resulted in a clin-
ically successful drug that improves thousands of lives
annually. Another clinically relevant example is that of
rostafuroxin, which is a simplified version of the toxic cardiac
glycoside ouabain.[122] This antihypertensive agent is currently
in phase IIb clinical trials and has been proven to be
especially effective for those with genetic abnormalities of
adducin and EO (endogenous ouabain) blood pressure
regulation. Gademann and co-workers demonstrated that
the known siderophore aachelin H could be truncated to its
chromophore and reapplied as an anchor to create antifouling
and antimicrobial surface coatings for potential use in
biocompatible medical devices.[123] In 1994, Nicolaou et al.
designed and synthesized truncated brevetoxin analogue
[AFGHIJK], which was able to bind to the voltage-gated
sodium channel and exhibit the same electrophysiological
activities as the parent, “red-tide” ladder polyether toxin with
an additional four rings.[119b,124] More recently, Overman and
co-workers reported the tBu-MacE analogue to have the
same Golgi-modifying properties as the parent spongian
diterpene macfarlandin E, but with even less cytotoxicity.[125]
Our last example is from the studies by Posner and
OÏNeill on analogues of the sesquiterpene trioxane artemi-
sinin. They have reported many simplified aryl derivatives
with comparable in vitro antimalarial activities in the nano-
molar range, which also function by the iron-induced trigger-
ing mechanism and were furthermore effective in rodent
models.[126]
3. Additional Sources of Natural Product Fragment
Lead Structures
This Review has focused on the identification of suitable
fragments through chemical synthesis. Looking toward the
future, however, recent advancements in structural biology,
computational chemistry, and genome mining show the
potential to identify suitable natural product fragments that
might be further refined by chemical synthesis.
A different approach to access novel, natural product
fragments based on genome data is fueled by advancements in
fields such as molecular biology, bioinformatics, genetic
mapping, and structural biology. Within the realm of nature,
DNA-encoding fragments of compounds are exchanged
between organisms and incorporated in new structures,
which can sometimes be found in different kingdoms.[127]
The natural product fragments are exchanged within organ-
isms by horizontal gene or fragment gene transfer. A
representative example is found in the pederin, theopeder-
in A, and onnamide A family of natural products, which share
common fragments.[128] The revolution in genome mining and
advances in metabolomics will continue to unearth even more
natural product structures, at an ever-increasing speed.
Anticancer antibody–drug conjugates (ADCs) are cur-
rently the biopharmaceutical standard for innovative cancer
treatments, with over 30 entities in clinical development.[129]
As the name suggests, an antibody is linked to a cytotoxic,
natural product derived “payload” to maximize targeting and
efficacy of the anticancer agent toward the diseased tissue.
Lead optimization in this field involves the development of
chemical conjugation methods to couple the natural product
to the antibody, the design of the linker, and the type of
antibody used.[130] Gemtuzumab ozogamicin (Mylotarg) was
the first clinically approved ADC. It was launched in 2000 in
the USA for the treatment of refractory acute myeloid
leukemia (AML), specifically for cells bearing the CD33
antigen.[129a, 131] It contains an N-acetyl-g-calicheamicin
dimethyl hydrazide derivative as its active agent, linked by
a pH-labile hydrazone fragment to a recombinant, humanized
IgG4 k antibody, developed byWyeth and UCB Pharma. This
success has led to the evaluation of other cytotoxins for this
type of cancer chemotherapy, including taxanes, ansamycins,
and duocarmycins.[130]
More recently, natural product derived fragments are
leading the next generation of ADCs for clinical develop-
ment.[129a] There are currently 33 ADCs with natural product
derived warheads, of which 10 are in phase II trials and 23 in
phase I trials. They are derivatives of calicheamicin g1,
dolastatin 10 (monomethylaurisatin E and F, MMAE and
MMAF), maytansine (DM1 and DM4), doxorubicin, SN-38
(camptothecin, irinotecan derivative), and anthramycin (pyr-
rolobenzodiazepine, or PBD, dimer; SGD-1882). It is an
exciting time in this relatively new field, as the technologies
continue to develop for the efficient production of these
natural product derived ADCs. Successful lead optimization
will likely launch this class of anticancer chemotherapies into
predominant clinical use, and eventually application toward
treatments of other diseases.
Although fragment-based drug design (FBDD) or screen-
ing libraries from diversity-oriented synthesis (DOS) seemed
to be the contending methods to approach drug development
in recent years, in the past 2–3 years we have seen a novel
tactic that combines these two methods and involves compu-
tational analysis and data mining to create or repurpose
natural product derived fragments (NPDFs).[132] This allows
for an elegant and systematic identification of biological
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targets for “orphan” natural products and/or NPDFs, which
can then be validated through chemical synthesis and
subsequent biological assessment. In the pioneering report
by Waldmann and co-workers in 2013, they disclosed an
innovative algorithm in which 2000 clusters of natural NPDFs
were generated from 180000 natural products, rich in sp3-
hybridized centers.[133] The overall concept was to identify
unexplored ligand classes and areas of chemical space for
established drug targets, especially those that have been
difficult to address. This approach combined the advantages
of the chemical space offered by fragments with the rich
chemistry and geometry that natural products bring, mean-
while leaving a possibility for optimization for biological
recognition and modulation.[132] As a proof-of-concept, they
screened and identified novel scaffolds as inhibitors of p38a
MAP kinase and tyrosine/dual-specificity phosphatases by
using protein X-ray crystallography. The term “biology-
oriented synthesis” (BIOS) has been coined by Waldmann
and co-workers for this method.[134]
In another example from 2014, Schneider and co-workers
developed a ligand-based model to predict biological targets
for NPDFs that does not require a three-dimensional target
model, but instead relies on the hypothetical polypharmaco-
logical character of natural products.[135] To validate their
method, they analyzed the antitumor agent archazolid A, and
identified eight new biochemical targets for this molecule, all
of which have been associated with antitumor effects. Addi-
tional work from the Schneider group has focused on
repurposing of de novo created compounds from computa-
tional models to predict bioactivity,[136] or on chemography by
creating a generative topographic map (GTM) to visualize
chemical space populated by natural products and synthetic
drugs.[137]
In 2015, Quinn and co-workers demonstrated that their
self-generated NPDF library captured more than half of the
small pharmacophore triplet diversity than other natural
product datasets,[138] and Lanz and Riedl used NPDFs as seeds
for the de novo discovery of lead structures for therapeuti-
cally relevant targets.[139]
Overall, these examples delineate a future for this field by
proving that the combination of bioinformatic/cheminfor-
matic tools with organic synthesis will enable scientists to
expand the boundaries of biologically relevant chemical
space.
4. Summary and Outlook
In this Review, we aimed to highlight how a desired
property of a natural product, such as its powerful biological
activity, can be retained by a smaller, truncated compound
(“reduce to the max”)—a refined fragment of the parent
natural product. This approach addresses some of the short-
comings of the use of natural products in drug discovery. The
chemical tractability can be greatly improved by structurally
more simple analogues, with fewer stereogenic centers and
often an overall drastically shorter synthetic route. In fact,
some of the resulting fragments resemble classical medicinal
chemistry targets with regard to size and complexity. In
addition, although considerable advances have been made in
synthetic methods over the last decades, chemical synthesis
alone cannot likely keep up with the de novo creation of
interesting natural product like scaffolds. As a result,
a number of potential avenues have opened up the future of
this field, including the use of natural product derived
fragments in antibody–drug conjugates, stereochemically
complex modules for fragment-based drug discovery, or
scaffold repurposing, as the next generation of natural
product-inspired therapies.
These, among other advancements in such fields as
structural biology, genetic mapping, protein crystallography,
computational chemistry, nanotechnology, and genome
mining show how natural product fragments can be used to
address some of the foreseeable challenges of innovative drug
development. All these combined approaches clearly present
a promising future role for natural products in drug develop-
ment. Innovation in these trajectories is key to the future of
natural product diversity having an impact on and expanding
the breadth of the drug discovery field.
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